# Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)

> **NCT00153998** · PHASE2 · COMPLETED · sponsor: **Technische Universität Dresden** · enrollment: 135 (actual)

## Conditions studied

- Colorectal Cancer
- Liver Metastases

## Interventions

- **DRUG:** Cetuximab
- **PROCEDURE:** Liver resection
- **DRUG:** Cetuximab and FOLFIRI
- **DRUG:** Cetuximab and FOLFOX

## Key facts

- **NCT ID:** NCT00153998
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2008-03
- **Final completion:** —
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2009-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00153998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00153998, "Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00153998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*